首页> 外文OA文献 >Peginterferon alfa-2a (40KD) plus 800 or 1000/1200 mg/day ribavirin in genotype 1 HIV–HCV co-infected patients: early responses to treatment and predictability for SVR in the PARADIGM study

【2h】

Peginterferon alfa-2a (40KD) plus 800 or 1000/1200 mg/day ribavirin in genotype 1 HIV–HCV co-infected patients: early responses to treatment and predictability for SVR in the PARADIGM study

机译：基因1型HIV-HCV合并感染患者中的Peginterferon alfa-2a（40KD）加800或1000/1200 mg / day利巴韦林：PARADIGM研究中对SVR的早期治疗反应和可预测性

页面导航

著录项
相似文献
相关主题

著录项

作者
Rodriguez-Torres M; Slim J; Bhatti L; Sterling R; Hassanein T; Clotet B; Branco T; Bertasso A; Stancic S; Sulkowski M;
展开▼
作者单位

展开▼
年度 2010
总页数
原文格式 PDF
正文语种 other
中图分类

相似文献

外文文献
专利

1. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin [J] . MarcellinP., ReauN., FerenciP., Journal of Hepatology: The Journal of the European Association for the Study of the Liver . 2012,第6期

机译：基于聚乙二醇干扰素α-2a（40KD）和利巴韦林治疗的HCV基因型1患者的第4周反应，基于第12周反应的精确预测
2. Sofosbuvir plus Peginterferon plus Ribavirin for 12 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients with Genotype 2 HCV Who Did Not Achieve SVR after 16 or 24 Weeks of Sofosbuvir plus Ribavirin [J] . Agarwal Kosh, Schultz Michael, Pianko Stephen, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：Sofosbuvir Plus Peginterferon Plus利韦利林在基因型中为12周，3个HCV感染患者和治疗经验丰富的肝硬化患者2 HCV在Sofosbuvir Plus利巴韦林的16或24周后没有达到SVR
3. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. [J] . Ferenci P, Formann E, Laferl H, Journal of Hepatology: The Journal of the European Association for the Study of the Liver . 2006,第2期

机译：peginterferon alfa-2a（40KD）加利巴韦林加金刚烷胺或不加金刚烷胺的随机，双盲，安慰剂对照研究在未经治疗的慢性丙型肝炎基因1型患者中进行。
4. Predictability of Sustained Virological Response (SVR) in Patients with HCV/HIV Co-infection During Combination Therapy With Peginterferon Alfa-2A (40KD) (PEGASYS~R) Plus Ribavirin (COPEGUS~R) in the APRICOT Trial [C] . M. Rodriguez Torres, F.J. Torriani, E. Lissen International AIDS Conference . 2004

机译：HCV / HIV与Peginterferon Alfa-2a（40KD）（Pegasys〜R）加上利韦韦林（Copegus〜R）在杏试验期间HCV / HIV CONOMENT患者持续病毒学反应（SVR）的可预测性
5. HCV RNA decline in the first 24 hours exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin [O] . N Laufer, F Bolcic, MJ Rolón, -1

机译：前24小时的HCV RNA下降表现出HIV / HCV基因型1患者持续的病毒学反应的高负预测值1其患有Peginterferon和利巴韦林治疗的患者
6. PIN53 COST EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN (RBV) FOR RE-TREATMENT OF HCV GENOTYPE I (Gl) PATIENTS WHO DID NOT RESPOND TO PREVIOUS HCV TREATMENT: A UK PERSPECTIVE [O] . Jensen DM, Marcellin P, Urspruch A, 2009

机译：英国人认为，PEG干扰素ALFA-2A（40KD）和利巴韦林（RBV）对未治疗过的HCV基因I型（GL）的患者进行再治疗的PIN53成本效益：

Peginterferon alfa-2a (40KD) plus 800 or 1000/1200 mg/day ribavirin in genotype 1 HIV–HCV co-infected patients: early responses to treatment and predictability for SVR in the PARADIGM study

著录项

相似文献

相关主题

期刊订阅